Abstract
Since recombinant human growth hormone (rhGH) was licensed for growth hormone deficiency(GHD) in 1985,it has been available in short stature associated with Turner syndrome (TS),being born small for gestational age,idiopathic short stature,chronic renal insufficiency in the last 20 years.The overall safety profile of rhGH continues to be favorable,but careful monitoring for the presence of certain conditions is important both during and after therapy.Reasonable indication,time of therapy and dosage are important to obtain the ideal result and save the expense.Besides,the efforts to improve rhGH therapy and increase compliance have also led to the investigation of extended-release rhGH and less invasive administration routes.Recent advances in the treatment of rhGH are reviewed in details. Key words: Recombinant human growth hormone; Growth hormone deficiency; Turner syndrome; Idiopathic short stature
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
